Adam Yusim (@AdamYusimBio) header
Adam Yusim (@AdamYusimBio) profile picture

Hindsight is infallible. Real edge is knowing luck from skill and pressing high-conviction bets. Clinical-stage biotech and equity research. Not advice.

Canada
Joined May 2023
Photo by Adam Yusim (@AdamYusimBio)Photo by Adam Yusim (@AdamYusimBio)Photo by Adam Yusim (@AdamYusimBio)Photo by Adam Yusim (@AdamYusimBio)Photo by Adam Yusim (@AdamYusimBio)Photo by Adam Yusim (@AdamYusimBio)Photo by Adam Yusim (@AdamYusimBio)Photo by Adam Yusim (@AdamYusimBio)Photo by Adam Yusim (@AdamYusimBio)
Adam Yusim retweeted
$SLS $CAPR $RVMD $ABVX I have long been a proponent of activist short sellers despite their unpopularity, because historically they have found bad actors that others missed. But in these last 2 weeks, they've very effectively shown that they no longer serve any purpose in biotech. Over the last 2 weeks, we have had $CAPR with outright fraud, and $SLS that has very clearly hidden their SAP on the HR they released. Two very high profile, very sketchy situations. One already confirmed by the FDA as outright fraud, the other...TBD. Meanwhile, over that exact same period of time, what biotech short reports did we get? First, we got a $RVMD short report that basically said "Hey, their patients are dying"...somehow managing to ignore the fact that THE PATIENTS HAVE PANCREATIC CANCER. Then, when got an $ABVX short report that essentially said "Hey, this drug actually has NOT shown evidence of carcinogenicity in humans, but maybe someday it will!" These arguments were so week that it boggles the mind to believe that previously well-respected actors would ever publish them. Both of these "reports" were riddled with blatant inaccuracies and even more false equivalencies. And what were they attacking? They were going after two companies that were easily two of the most impressive stories biotech has generated throughout the 2020s. $RVMD moved the line further in pancreatic cancer than anyone has ever moved it before, with novel technology that they created! $ABVX salvaged a defunct HIV drug and discovered it was actually the most effective ulcerative colitis drug of all time (as measured by the now universally accepted key endpoint in UC - maintenance phase endoscopic remission). Two weeks. Two blatant fraud companies that the "activist short sellers" chose to completely ignore. Two short reports published to slander two of biotech's greatest beacons of success in this decade. Supposed activist short sellers used to actually look for fraud...now they just look for a widely owned name that has had success, make outrageous headline claims about it to cause a brief drop in the stock price, and put in the disclaimers section that they're actively covering their position on the drop they created. Shameful. Seriously shameful. The good news is, it won't work forever. When you beclown yourself like this enough times, everything you say stops having any impact. But man, the evolution of these "activist short sellers" from what they used to be into what they are today...what an embarrassment.
6
4
3
77
2,999
Scorpion calls the $ABVX obefazimod program a “fraud.” I went through the numbers behind that allegation. Start with the two that do the most work in the headline: 8.4× and 4×. The 8.4× tells us how far obefazimod’s UVA absorption exceeded a screening threshold for further photosafety assessment. Scorpion’s experiment did not measure damage to human skin, tumor formation or cancer risk. As far back as 2022, Abivax’s public protocol disclosed preclinical phototoxicity of the metabolite and called for dermatologic surveillance. That risk was under investigation four years before Scorpion published its report. The 4× comes from 4 nonmelanoma skin cancers among 195 patients on 50 mg, versus 1/192 on placebo, over 44 weeks of randomized maintenance. At 25 mg, it was 1/193. One detail matters: the placebo patient who developed skin cancer had received 50 mg during induction. Establishing whether the drug raises long-term cancer risk takes far more patients, years of exposure and an appropriate comparator. Scorpion also presents no evidence of oncogenic virus reactivation in these cases. Its own hypothesis centers on UVA exposure. Obefazimod’s efficacy in ulcerative colitis has been demonstrated. In two separate Phase 3 induction trials, clinical remission on 50 mg versus placebo was 21.7% vs 2.5% and 19.8% vs 6.3%. In the third Phase 3 trial, among induction responders, 50.8% on 25 mg and 51.3% on 50 mg were in remission at week 44, versus 10.4% on placebo. Endoscopy confirmed the benefit as well. If Scorpion is going to call three Phase 3 trials a fraud, show us which clinical data were falsified and how correcting them changes the result. I couldn’t find that evidence in 297 pages. We added to our $ABVX position at $65.
1
3
34
2,102
Adam Yusim retweeted
Replying to @ScorpionFund
@ScorpionFund So Scorpion wants you to believe $ABVX management are so sophisticated and skilled at subtle subterfuge and coercing of CROs and trial site PI’s to orchestrate this clinical data heist of the century… …but this is also the same management team that misattributed a non-cancer finding in a patient (colonic dystonia) to a cancerous finding (non-NMSC), and then created an unfortunate safety slide that led to the inadvertent conclusion by some that there was an imbalance. If you were really focused on covering this up, wouldn’t you probably be trying to make it appear that there are LESS cases of cancer than in truth, rather than MORE? Really ironic that $ABVX own screwed up execution on their safety data could actually be exonerating to them in this report 🤣🤣🤣
7
1
1
90
4,284
Adam Yusim retweeted
Few important things to address 1) Nature is healing $capr goodnight. 2) $mrna -30% from highs and counting 3) on Scorpion, I wanna to address his $slno slander first. He wasn’t right on Vykat? The drug is on market doing $400m+ a year and a half in? He doesn’t get to victory lap on $slno .. bear in mind he said it was a 0 , acquired for $2.9B! And growing every quarter since launch ABOVE consensus…. 4) it’s personal with this guy and he made it personal a very long time ago (also what’s with my mention in the report??? “Bag holder” … yes happy bag holder from $8…..) gonna take the weekend to draft a response on $abvx
10
6
164
12,303
Adam Yusim retweeted
Scorpion's weak $ABVX bear thesis is now pivoting to "But the North American enrollment rates were low so the data must be fake!!!" Legitimately, 5 minutes of very simple diligence derails his point entirely, showing proof of concept to even LOWER North American enrollment rates leading to approval. I am very serious in asking this question...Did they even look into this enrollment data *at all* before making it a key point of their bear thesis?
Replying to @ScorpionFund
Also, legitimately WTF are you talking about with this "ex-North America" enrollment bear thesis for $ABVX? Did you even try a 30 second prompt in an LLM during your supposed 11 months of "research" here? This point doesn't even stand to very basic scrutiny. your bear point is that "only" ~10% of $ABVX patients were enrolled in North America...So? Seriously about 2 minutes with an LLM could tell you this is NOT an outlier at all. 1⃣LUCENT-1 P3 study of mirikizumab in UC ➡️ ~13% North American enrollment 2⃣LUCENT-2 P3 study of mirikizumab in UC ➡️~13% North American Enrollment 3⃣ELEVATE-UC P3 study of etrasimod in UC ➡️~9% North American Enrollment 4⃣QUASAR IS-2 P3 study of guselkumab in UC ➡️5% North American Enrollment (after the P2b study IS-1 ALSO had 5% North American patient enrollment. All of these are **FDA approved** therapies for UC today...This COMPLETELY debunks a hinge point of your entire bear case about there being something odd about $ABVX having 10% of patients enrolled from North America. I am being completely serious here and I want your response. DID YOU EVEN CHECK WHAT THE "NORMAL" RATES OF NORTH AMERICAN TRIAL SITE ENROLLMENT WERE IN ULCERATIVE COLITIS BEFORE YOU MADE THIS A LITERAL HINGE POINT OF YOUR BEAR THESIS FOR $ABVX? This is truly *laughably* poor work. Readily available PoC shows FDA approval in UC on datasets not only with NA enrollment rates ~around $ABVX's, but with even *lower* rates than $ABVX has! The Guselkumab (FDA approved as Tremfya) trial had literally HALF the percentage of North American patient enrollment has $ABVX! HALF!!! So again, I ask you...did you even bother to check into this before basing a huge chunk of your thesis on this point? Because it doesn't stand up to 30 *seconds* of midwit LLM diligence. Here's a source for you too so that you can do the numbers yourself if you want. clinicaltrials.gov/study/NCT… This Tremfya P3 (IS-2) had 17 patients on drug from US, and 5 from Canada. 11 patients on placebo from US and 2 from Canada. 17+5+11+2 = 35. 35/701 total patients = 4.99%. HALF the percentage of NA patient enrollment from this P3 study (that led to an FDA approved drug) as $ABVX's ~10% rate. Run the numbers on the P2b from IS1 in the same link - it's *also* 5% NA enrollment...Hello??? You're claiming that $ABVX is in trouble because of supposedly "low" NA enrollment rates...while the readily available proof of concept shows the rate can be HALF of what $ABVX has and *still* lead to approval. And this is supposedly one of your key findings you spent 11 months on? Debunking this didn't take me 11 minutes. Awful dude - absolutely piss poor.
15
5
1
133
13,073
Adam Yusim retweeted
Replying to @ScorpionFund
$ABVX Oh now this is utter bullshit. You're not even telling the truth about what your own thesis was on $SLNO! you $SLNO safety problem thesis was largely based on REAL WORLD HUMAN data for that drug that had already existed for DECADES. That drug (diazoxide) had been used in other settings outside of where $SLNO was studying it for a long, long, time and there was already real world evidence of the exact side effects that you were highlighting. That had nothing to do with any preclinical work you did on the drug! The side effects of diazoxide were literally already known for decades. It was first approved in 1973!!! your thesis there had summarily ZERO to do with whatever preclinical work you did, and the real world safety data showing an existing safety issue were already freely available in a wealth of medical literature. This is literally the exact OPPOSITE of what you're proposing with $ABVX where the preclinical work is your entire claim and the REAL WORLD DATA DISPROVE IT. Literally the EXACT opposite of the $SLNO/diazoxide case. Your arguments here are so poor that it is truly bizarre to see you descending to this level.
6
8
2
187
12,577
Adam Yusim retweeted
Replying to @ScorpionFund
At least your $SLNO report was based on actual in-human data. What you're saying about $ABVX is late to the story wet lab speculation that has already debunked by the existing in human data which very clearly show malignancy rates within or below the expected background rates...Which even your own tables show! BTW, you seem not to know this, but institutional investors ran these lab studies that you just did years ago already, and those same people ended up becoming some of the company's biggest bulls and current investors. I know you think you published something new here - you didn't. The AhR stuff is old old news. Years late to the story, and the in human data have already played out to $ABVX's favor. I could go on and on listing the absurdities in this document...discussing monkey tox concerns at 500mg/kg/day (~1000x the human dose!!!), concerns over "Chinese data" when ABTECT-2 had literally ZERO Chinese trial sites. You point out preclinical phototoxicity signals and speculate that the company didn't know or didn't do anything about it...yet enhanced skin surveillance was BUILT INTO THE STUDIES PROSPECTIVELY by the company! The company itself not only knew about this, but literally specifically designed the studies to test phototox concerns and either confirm it or rule it out....WHICH IT ULTIMATELY DID rule out. Pointing out that the parent molecule is lipophilic and using that to call it an "agrochemical"... Just laughable sensationalism. We have known the structure of this molecule for over a decade. And BTW, plenty of drugs have lipophilic properties. This is a bizarre and irresponsibly over-sensationalized bit...calling it an "agrochemical"... BTW, your own malignancy event table shows a malignancy rate BELOW background rates....??? You point out that there were zero remissions the placebo arm in one of the trials in the US and call that an outlier that will concern regulators....the expected number of patients to respond in that arm per the results of the rest of the study would have been 1.6 responders on the placebo arm! 0 instead of 1...that's an anomolous signal to you? So ultimately your bear argument is this: "This drug has NOT shown increases in cancer in patients. In fact, it has shown rates at or even BELOW the rates of other drugs approved for this disease that have no black box warning for cancer. But hey, who knows, maybe that will change someday down the road!" BTW, you're aware there's an FDA approved AhR drug on the market already right? One with no cancer risk... You're claiming that AhR agonism is the top secret *true* mechanism of $ABVX's obefazimod and that this is bad because you claim AhR agonism is going to cause cancer... Again, not only is the AhR agonism theory that you're treating as a revelation actually a point that $ABVX *bulls* have believed for literally years already (i.e. not news from you), but there is actually a drug ON THE MARKET today that literally has that as its exact mechanism of action...and it has no labeled risk of carcinogenicity and no studies in humans or animals supporting carcinogenic risk....So you go through all this bluster about AhR pretending it is news (it isn't) and then claiming it is going to cause cancer (even though the data we have very clearly show that it HASN'T), meanwhile, there's already been an AhR drug on the market for years that has never shown a single piece of evidence for carcinogenicity... Like I have said in the past - I had previously agreed with some of your work. This piece is irresponsibly poorly done and the use of the word "fraud" is absolutely egregious and slanderous when your thesis ultimately boils down to..."well, they haven't shown cancer signals yet, but maybe they will someday!" Calling this fraud with the evidence you provide sincerely rises to the level of libel, in my opinion.
11
18
2
251
31,772
Adam Yusim retweeted
$ABVX 1) This (see screenshot), and 2) Now we now why the stock had gotten so weak in the $80s. I'm actually relieved that I now have an explanation for that. It's legitimately a relief to find out that the seemingly inexplicable weakness in $ABVX was due to a short report that truly lacks *any* semblance of substance, or frankly even basic coherence (what even is the final claim/proposition???). Scorpion will make some money covering on the dip that they created (like they literally admit that they are doing within the short report itself). I suspect that the amount of money that biotech specialist funds will make buying off of this absurdity will completely dwarf whatever scraps Scorpion is taking off the table here. I'd tell you that "I look forward to looking back at this and laughing about it someday", but the problem is...I literally already am today!
12
10
2
209
21,026
Adam Yusim retweeted
$abvx Abivax reportedly turned down a $17 billion buyout offer and went on to assemble a dream team of ulcerative colitis experts. It’s hard to believe a company would make moves of that magnitude if management knew it was sitting on a mountain of fraudulent data. The actions simply don’t align with that narrative
7
3
1
69
7,335
Adam Yusim retweeted
$ABVX Scorpion report is just silly. The entire argument is based on preclinical wet lab "research". The report makes all these outlandish claims about what the drug "might" do based on their lab work, then ignores that all of those potential "problems" have been completely debunked by ACTUAL REAL WORLD DATA. The drug is post phase 3 already people. We already know the safety profile. The theories they published in this "short report" are *literally* the exact bear theses people were talking about 6 years ago for $ABVX. Wet lab based *theories* about the molecule itself. The difference today is that.....we literally have all the real world in human data now, AND NONE OF THOSE SCARY THEORIES TURNED OUT TO BE TRUE. I'm with @Biohazard3737 - I increased by exposure to $ABVX this morning. I suspect that this report coming out also explains the recent weakness in the stock. Scorpion has supposedly been working on this for 11 months. Word going around about this report is probably what caused that short report rumor and flash crash back in June too. And since then, we got EVEN MORE data proving the safety concerns are debunked. I have been baffled by even seeing the stock languishing in the $80s recently. Now I understand why that's been the case. I've already talked to a lot of smart people on this. The near universal response is laughter/mockery. This is simply not serious work. Congrats to Scorpion though for finding a weak stock to attack and then cover your short on a Friday Opex. $ABVX will be fine.
41
28
6
393
37,752
Adam Yusim retweeted
Replying to @GravityAnalyti1
Ok now that is something I actually find extremely offensive. I challenge you to find someone else here who more thoroughly and repeatedly highlights the risks associated with the stocks they choose to discuss. I *constantly* repeat the risks of stocks I am involved in. I do it in all caps, bold, red font, highlighted. Repeating the same disclaimers over and over and over. At the start of pitches, in the middle, and at the end. Over and over and over. This is EXTREMELY important to me. "But you don't seem even consider the people who you post to aren't high income". Fuck you. Look at the screenshots of me LITERALLY WARNING SPECIFIC INDIVIDUAL PEOPLE ABOUT THE RISKS THIS VERY MONTH. And for the record, I've been broke too. Investing in biotechs is how first I became not broke. You can say what you want about my investing ability (while making an absolute fool of yourself in the process). I have 1,000 haters like you who will say I suck no matter how many triple digit % years I produce. But discussing risk is something I take EXTREMELY seriously and PERSONALLY, and I'm not letting you spew absolute fucking nonsense to the contrary here. Read a small sample of the receipts. What more could you possibly ask for? As far as I'm concerned the only other option would be to simply discuss no stocks at all. Then I'd be as useless as you.
23
1
1
222
43,204
Adam Yusim retweeted
A lesson we all should take seriously, thank you @ShawnEni. Jews supported Hitler. One in particular, a Jewish Lawyer wrote most of the anti-Jewish laws that progressively tightened the noose around their necks. Those laws, to a law-following German, proved how evil the Jews were. Jews in the US have long supported the Democrat party. For anyone who can see, that is already ending badly. Islam is the future of the Democrat party. Jews that think they can safely support the likes of Mamdani or El-Sayed and the Democrats of today are just as deluded as Max Naumann. Wake up before it is too late.
Let me introduce you to a fellow named Max Naumann. In 1934, Naumann, a German Jew, urged fellow Jews to support Adolf Hitler. He defended the Nazi regime even as it persecuted Jews, and actually petitioned Hitler for the right of Jews to fly the German flag. In 1935, the Gestapo dissolved his organization and threw him in prison, where he attempted suicide. He died of cancer in 1939, before the Holocaust, but not before discovering how little his loyalty to the Nazis was worth. I'm not comparing Abdul El-Sayed to Hitler. I'm questioning the idea that a Jewish endorsement is, by itself, evidence of what's best for Jewish safety. From the Hellenizing Jewish elites of ancient Jerusalem to Jewish supporters of Iran's Islamic Revolution, we have examples throughout our history of Jews aligning themselves with political movements that ultimately turned against them. Their motivations differed, as did the consequences. But there's a lesson in Max Naumann's story that's worth remembering. Being Jewish has never made anyone immune to being catastrophically wrong about what's good for Jews. @PatinkinMandy @GadSaad
1
1
1
5
533
$MRNA Not a single insurance company in the world is going to underwrite at $400,000 treatment for an additional 12% overall survival rate compared to paying $10,000 for just Keytruda which does the same shit. That’s the bottom line. Game over. $MRK $QQQ $SPY
10
3
2
70
22,023
Adam Yusim retweeted
$MRNA Investors Should Brace for More Whiplash Even after its sharp fall, the drugmaker’s stock price assumes wild successes wsj.com/health/pharma/modern…
2
5
3
35
21,164
Adam Yusim retweeted
Replying to @RNAiAnalyst
….every successful cancer drug’s HR in history gets better if you exclude the first 6 months of treatment. What are you trying to get at here? I really don’t understand the cherry picking?
2
1
25
3,490
Adam Yusim retweeted
$MRNA "Reduced the risk of recurrence or death by 42%" AKA patients are still dying of cancer AKA it's not a cure. Surprise! Your vaccine company you were bidding up to insane levels doesn't do the thing you thought it did and now you're left with a company trading at 100x peak revs.
12
10
2
82
18,619
Adam Yusim retweeted
Replying to @deathtouch2k
NNT worse than expected I’d wager
1
1
7
2,263
Adam Yusim retweeted
Last 3 months: “Biotech is down every day because $MRNA and yields are up every day.” Today: “$MRNA and yields are plummeting!” *Biotech immediately joins them in jumping off the cliff* Honestly folks, why do we even do this?
24
4
3
151
19,725
Adam Yusim retweeted
$MRNA with the single most hilarious possible outcome in this study. EFS HR 0.58. Down the the hundredth, EXACTLY what *NEO*-adjuvant treatment with pembro yielded against adjuvant pembro (the nerfed comparator $MRNA studied against) in SWOG S1801. What does this mean in English? $MRNA’s drug is showing the exact same benefit versus adjuvant pembrolizumab as NEOadjuvant pembrolizumab did. Even more simply? If you just give patients a few doses of the pembrolizumab BEFORE you cut their cancer out, you do what $MRNA does for you, except with just the free tumor that’s already inside your body. No need to pay for this $400K drug. And this makes rational sense, right? The whole point of $MRNA’s vaccine is to produce stuff that looks like the tumor. You know what looks A LOT like the tumor does? THE FREAKING TUMOR!!!!!! Absolutely poetic that $MRNA produced the EXACT HR benefit as neoadjuvant pembro did. Truly, the most hilarious possible outcome. Now can we move on from this bullshit? $MRK and $MRNA should feel free to study their vaccine against the REAL standard of care now - NEOadjuvant immunotherapy. From my perspective, this has been total fugaze, and an amateurish pump and dump worthy of much lesser enterprises.
80
84
60
580
230,159
Replying to @markflowchatter
There is no such thing as positive data from $MRNA. In case you forgot, they defrauded the entire world.
6
1
9
2,337